Abstract：Objective: To investigate the protective effect of sacubatre and valsartan on vascular endothelial function in patients with hypertension and chronic heart failure. Methods: A total of 159 patients with hypertension and chronic heart failure were simply randomly divided into observation group and control group, 80 cases in the observation group and 79 cases in the control group. The control group was treated with valsartan, and the observation group was treated with sacubitril valsartan, and both groups were treated for 6 months. The brachial artery endothelium-dependent vasodilation (EDD) function, serum nitric oxide (NO), endothelin-1 (ET-1), carotid intima-media thickness, glomerular filtration rate and left ventricular ejection fraction were compared between the two groups before and after treatment. Results: There was no significant difference in EDD, NO and ET-1 between the two groups before treatment (P>0.05). After treatment, compared with the control group, the EDD function of the observation group was significantly increased [(11.78 ± 3.25) vs (10.15 ± 3.17)%, P=0.002], the NO level was significantly increased [(97.24 ± 6.21) vs (82.61 ± 5.35) μmoL / L, P=0.000], and the ET-1 level was significantly decreased [(42.21 ± 7.14) vs (50.42 ± 6.36) ng / L, P=0.000]. There was no significant difference in carotid intima-media thickness, glomerular filtration rate and left ventricular ejection fraction between the two groups before and after treatment (P>0.05). Conclusion: Sacubitril valsartan have protective effect on vascular endothelial function in patients with hypertension and chronic heart failure.
李娜, 古丽孜热木·阿布都马那甫. 比较沙库巴曲缬沙坦和缬沙坦对高血压合并慢性心力衰竭患者血管内皮功能的影响[J]. 河北医学, 2021, 27(7): 1223-1226.
LI Na, GULIZIREMU Abudumanafu. Comparison of the Effects of Valsartan and Salcubatrium on Vascular Endothelial Function in Patients with Hypertension and Chronic Heart Failure. HeBei Med, 2021, 27(7): 1223-1226.
[1] Saitoh M,Dos Santos M R,Emami A,et al.Anorexia,functional capacity,and clinical outcome in patients with chronic heart failure: results from the studies investigating comorbidities aggravating heart failure (SICA-HF) [J].Esc Heart Failure,2017,4(4):448~457. [2] 汪丽娜,王晓艳,姜红,等.西安市居民膳食磷摄入与高血压罹患的关联性研究[J].中国食物与营养,2020,26(12):80~85. [3] Pieske B,Maggioni A P,Lam C S P,et al.Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the soluble guanylate cyclase stimulator in heArT failure patients with preserved ef (Socraes-preserved) study[J].EurHeart,2017,38(15):1119. [4] 王毅,杨征.托伐普坦和沙库巴曲缬沙坦钠片对慢性心力衰竭患者心功能及血清钠水平的影响研究[J].陕西医学杂志,2019,48(4):64~66. [5] 李江,曹佳宁,丹增洛布,等.沙库巴曲缬沙坦钠片治疗高原地区高血压慢性心力衰竭患者的临床效果[J].中国医药,2019,14(3):9~12. [6] Penna C,Tullio F,Femmino S,et al.Obestatin regulates cardiovascular function and promotes cardioprotection through the nitric oxide pathway[J].Cell Mol Med,2017,21(12):783~788. [7] Maruhashi T,Iwamoto Y,Kajikawa M,et al.Interrelationships among flow-mediated vasodilation,nitroglycerine-induced vasodilation,baseline brachial artery diameter,hyperemic shear stress,and cardiovascular risk factors[J].Am Heart Assoc,2018,7(1):e797~e803. [8] Chester A H,Yacoub M H.The role of endothelin-1 in pulmonary arterial hypertension[J].Glob Cardiol Sci Pract,2017,2014(2):62~78. [9] Wu Q,Cao Y,Mao G,et al.Effects of forest bathing on plasma endothelin-1 in elderly patients with chronic heart failure: Implications for adjunctive therapy[J].Geriatr Gerontol Int,2017,17(12):2627~2629. [10] Rossi G P,Seccia T M,Barton M,et al.Endothelial factors in the pathogenesis and treatment of chronic kidney disease part I: general mechanisms a joint consensus statement from the european society of hypertension working group on endothelin and endothelial factors and The Japanese society[J].Hypertension,2018,36(3):1~10. [11] Zimmer A,Teixeira R B,Bonetto J H P,et al.Effects of aerobic exercise training on metabolism of nitric oxide and endothelin-1 in lung parenchyma of rats with pulmonary arterial hypertension[J].Mol Cell Bioch,2017,429(2):73~89.
2021, Vol. 27 
冀公网安备13080202000677号